Winstrol (Oral)
Stanozolol · Winny
Oral stanozolol; cutting agent, joint pain common. Simple model — peak calibrated.
Overview
Winstrol (stanozolol) is an oral DHT derivative, 17-alpha-alkylated with an added pyrazole ring, developed in 1962 and best known as a cutting agent that builds strength without estrogenic water retention. It binds the androgen receptor and, uniquely among oral AAS, lowers SHBG, which raises the free fraction of co-administered hormones (a real interaction risk). It does not aromatize and is not further 5-alpha-reduced. Its 9-hour half-life drives the standard twice-daily split dosing used in research protocols. Hepatotoxicity is rated moderate, so liver enzymes and lipids (HDL/LDL) are the central harm-reduction concerns. Joint pain is also commonly reported because the drug reduces water and synovial lubrication. HPTA suppression is rapid and dose-dependent.
Pharmacokinetic summary
- Model tier
- Simple (t½ + F, Tmax estimated)
- Half-life
- 0.4 days
- Cmax
- 49.9 ng/dL
- Bioavailability
- 100%
- Typical dose
- 20–50 mg
Harm reduction
- Aromatizes
- No
- DHT derivative
- Yes
- Hepatotoxicity
- moderate
- Injection frequency
- Oral, 2×/day
Related compounds
Halotestin
Extremely hepatotoxic oral; pure strength/aggression, minimal hypertrophy.
Anadrol
Potent oral mass builder; high water retention and significant hepatotoxicity.
Dianabol
Classic oral mass builder; short half-life, strong aromatization. Simple model — peak calibrated.
Protocols featuring Winstrol (Oral)
Comments
Loading comments…